代偿失调的乙型肝炎肝硬化的补偿：现状和挑战

StephenW

Recompensation of Decompensated Hepatitis B Cirrhosis: Current Status and Challenges
Hong Zhao  1 , Qi Wang  1 , Changling Luo  1 , Ligai Liu  1 , Wen Xie  1
Affiliations
Affiliation

    1
    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, 8 East Jingshun Road, Chaoyang District, Beijing, China.

    PMID: 33029534 PMCID: PMC7527887 DOI: 10.1155/2020/9609731

Abstract

Liver-function decompensation or hepatocellular carcinoma (HCC) gradually appears after chronic hepatitis B progresses to cirrhosis. Effective antiviral treatment can significantly improve the long-term prognosis of decompensated patients, and some patients present recompensation of decompensated hepatitis B cirrhosis. At present, there are limited research data on the recompensation of decompensated hepatitis B cirrhosis. There is still controversy regarding the evaluation time, evaluation indicators, influencing factors, and long-term prognosis of recompensation.

Copyright © 2020 Hong Zhao et al.

StephenW

代偿失调的乙型肝炎肝硬化的补偿：现状和挑战
洪昭1，王琦1，罗长岭1，刘立盖1，文谢1
隶属关系
联系

    1个
    首都医科大学附属北京地坛医院肝病中心，北京市朝阳区京顺东路8号。

    PMID：33029534 PMCID：PMC7527887 DOI：10.1155 / 2020/9609731

抽象

慢性乙型肝炎发展为肝硬化后，肝功能失代偿或肝细胞癌（HCC）逐渐出现。有效的抗病毒治疗可以显着改善失代偿患者的长期预后，并且一些患者可以弥补失代偿的乙型肝炎肝硬化。目前，关于代偿失调的乙型肝炎肝硬化的补偿的研究数据有限。关于评估时间，评估指标，影响因素以及补偿的长期预后仍存在争议。

版权所有©2020 Hong Zhao等。

StephenW

https://www.hindawi.com/journals/bmri/2020/9609731/